Navigation Links
Frost & Sullivan Lauds Carl Zeiss Meditec for Dominating the OCT Market for Ophthalmic Applications
Date:3/31/2009

MOUNTAIN VIEW, Calif., March 31 /PRNewswire/ -- Based on its recent analysis of the optical technologies market, Frost & Sullivan recognizes Carl Zeiss Meditec with the 2009 North American Frost & Sullivan Market Leadership Award for its optical coherence tomography (OCT) technology for ophthalmic applications. Carl Zeiss Meditec is a pioneer of OCT technology and has launched clinical tools that revolutionized the diagnosis and treatment of eye diseases.

(Logo: http://www.newscom.com/cgi-bin/prnh/20081117/FSLOGO)

Carl Zeiss Meditec was the first to introduce Time Domain (TD) OCT-based innovative products for retinal, anterior segment/cornea, and glaucoma imaging. More recently, the company introduced the next generation of Fourier Domain (FD) OCT-based product line for ophthalmic applications.

"Multiple start-up companies have introduced promising FD OCT-based products, creating an increasingly competitive dynamic," says Frost & Sullivan Senior Research Analyst Madhu Sharma, Ph.D. "Nonetheless, Carl Zeiss Meditec has responded by implementing an innovation-centric strategy focused on continually presenting novel products and thereby, maintaining a dominant market position."

The company's OCT systems are one of the most widely adopted clinical tools among ophthalmologists. The Stratus OCT(TM) and new Cirrus(TM) HD-OCT systems offer proficiencies and streamlined workflows that allow physicians to gather and interpret detailed disease information.

Additionally, the company has developed proprietary image analysis algorithms that provide volumetric data and aid in interpreting three dimensional images in a highly reproducible and quantitative fashion. It continues to invest in upgrading software for objective measurement and subjective clinical evaluation of retinal disease detection. To cement its strong market position, it has also increased spending in optical technology R&D.

Apart from providing advanced imaging capabilities, Carl Zeiss Meditec offers unparalleled customer service. With its innovative technology and excellent support to the end-users, the company has established a very loyal customer-base and continues to expand its presence. It has an outstanding customer care solution organization that recruits highly trained staff to assist customers and provide quality replacement parts and supplies. The company provides in-house technical support and best-in-class email, online and telephone support. In addition, it offers an array of technical training opportunities to facilitate the process of new product adoption.

"Carl Zeiss Meditec received the highest overall Frost & Sullivan Competitive Metrics Score in the recently completed Strategic Analysis of Optical Imaging Technologies in U.S. Clinical Diagnostics Markets," continues Dr. Sharma. "The company's high scores are tied to its success in the OCT Technology segment of the Analysis."

With an overall score of 10.22, Carl Zeiss Meditec received tier I scores in all four categories of 'market positioning and growth,' 'innovative performance,' 'growth strategy,' and 'leveragable assets'. The score break-up is 2.67 for 'market positioning and growth,' 2.33 for 'innovative performance,' and 2.61 for 'growth strategy.' The Company's overall score is over 2.2 points higher than the average of the other participants, which received a combined score of 8.01.

In short, its careful attention to product quality, breadth of product line, excellent customer support, and reputable brand name has earned Carl Zeiss Meditec a leadership position in the OCT technology market for ophthalmic applications.

Each year, Frost & Sullivan presents this award to the company that has exhibited market share leadership by excelling in all areas of the market leadership process, including the identification of market challenges, drivers and restraints, as well as strategy development and methods of addressing market dynamics. Furthermore, the Award recipient has continually demonstrated solutions for monitoring market changes and implementing superior market strategies.

Frost & Sullivan's Best Practices Awards recognize companies in a variety of regional and global markets for demonstrating outstanding achievement and superior performance in areas such as leadership, technological innovation, customer service, and strategic product development. Industry analysts compare market participants and measure performance through in-depth interviews, analysis, and extensive secondary research in order to identify best practices in the industry.

About Carl Zeiss Meditec

Carl Zeiss Meditec AG (ISIN: DE 0005313704), which is listed on TecDAX of the German stock exchange, is one of the world's leading medical technology companies.

The Company supplies innovative technologies and application-oriented solutions which enable doctors to improve the quality of life of their patients. The Company offers complete solutions, including implants and consumables, to diagnose and treat ophthalmic diseases. In the field of Neuro/ENT surgery the Company provides innovative visualization solutions. Carl Zeiss Meditec's medical technology portfolio is rounded off by promising future technologies such as intraoperative radiotherapy.

The Company's around 2,100 employees generated revenue of about EUR 600 million in fiscal year 2007/08 (ended Sept. 30). The headquarters of Carl Zeiss Meditec are located in Jena, Germany. In addition to other subsidiaries in Germany, the Company is represented by over 50 percent of its employees at sites in the USA, Japan, Spain and France.

Thirty-five percent of Carl Zeiss Meditec's shares are in free float. The remaining 65 percent are held by Carl Zeiss AG, one of the world's leading groups engaged in the optical and opto-electronics industry. The five independently run business segments of Carl Zeiss AG operate in the future-oriented markets "Medical and Research Solutions", "Industrial Solutions" and "Lifestyle Products". Carl Zeiss AG is headquartered in Oberkochen, Germany. During fiscal year 2007/08 (ended Sept. 30) the company generated revenues of about EUR 2.7 billion. Carl Zeiss has around 13,000 employees in more than 30 countries, including more than 8,000 in Germany.

For further information please visit our website at: www.meditec.zeiss.com

About Frost & Sullivan

Frost & Sullivan, the Growth Partnership Company, enables clients to accelerate growth and achieve best in class positions in growth, innovation and leadership. The company's Growth Partnership Service provides the CEO and the CEO's Growth Team with disciplined research and best practice models to drive the generation, evaluation and implementation of powerful growth strategies. Frost & Sullivan leverages over 45 years of experience in partnering with Global 1000 companies, emerging businesses and the investment community from 31 offices on six continents. To join our Growth Partnership, please visit http://www.frost.com.

    Contact:
    Jake Wengroff
    210.247.3806
    jake.wengroff@frost.com


'/>"/>
SOURCE Frost & Sullivan
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Frost & Sullivan Hosts Presentation on MicroRNAs: From Stem Cells and Cancer to Diagnostics and Therapeutics
2. Frost & Sullivan Award Highlights Opportunity for Main Street Biotech
3. Frost & Sullivan Recognizes Life Technologies for Excellence in the Life Science Research Tools Industry
4. Frost & Sullivan Recognizes Excellence in Medical Technologies & Life Sciences
5. Frost & Sullivan Recognizes Nanopoint for its Pioneering Cell Imaging Solution, the cellTRAY(R) Imaging System CT-2000
6. Frost & Sullivan: In Vitro Diagnostics Market
7. Frost & Sullivan Recognizes Novagali Pharma for Innovation in Ophthalmic Therapies
8. Frost & Sullivan European Drug Discovery Product Innovation Award Bestowed on Xenometrix AG
9. Frost & Sullivan Recognizes ApaTechs Leadership in Orthopedic Biologics
10. The Need for Safe and Affordable Biopharmaceuticals Drives the Development of the European Biosimilars Market, Says Frost & Sullivan
11. Magellan to Receive Frost & Sullivan 2009 North American Product Innovation Award; Three-Minute LeadCare(R) II Test Identifies Children with Lead Poisoning
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/12/2016)... MedGenome,s Commitment Will Help ... of Complex Diseases Such as Cancer, Metabolic Disorders, ... --> --> MedGenome, the market ... leading provider of genomics research services globally, today ... GenomeAsia 100K consortium as a founding member. ...
(Date:2/11/2016)... , Germany and ... QGEN ; Frankfurt Prime Standard: QIA) today ... Targeted RNA Panels for gene expression profiling, expanding QIAGEN,s ... (NGS). The panels enable researchers to select from over ... changes and discover interactions between genes, cellular phenotypes and ...
(Date:2/11/2016)... ... February 11, 2016 , ... ... cutting-edge information focused on the development and manufacture of biopharmaceuticals and therapeutics, ... sponsor of the 2016 BioProcess International Awards – Recognizing Excellence in the ...
(Date:2/11/2016)... , ... February 11, 2016 , ... ... more than 150 years, continues today to pursue the highest level of accuracy ... analytical instruments: the AR9 Refractometer and the AR5 Refractometer. Accurate, reliable and ...
Breaking Biology Technology:
(Date:2/3/2016)... , February 3, 2016 ... new market research report "Automated Fingerprint Identification System Market ... Latent Search), Application (Banking & Finance, Government, Healthcare, and ... by MarketsandMarkets, the market is expected to be worth ... of 21.0% between 2015 and 2020. The transformation and ...
(Date:2/2/2016)... 2016 Checkpoint Inhibitors for Cancer – ... Are you interested in the future of cancer ... inhibitors. Visiongain,s report gives those predictions to 2026 ... level. Avoid falling behind in data or ... revenues those emerging cancer therapies can achieve. There ...
(Date:2/1/2016)... NEW YORK , Feb. 1, 2016  Today, ... Heart Association (AHA) announced plans to develop a first ... cognitive computing power of IBM Watson. In the first ... disease, AHA, IBM (NYSE: IBM ), and Welltok ... metrics and health assessments with cognitive analytics, delivered on ...
Breaking Biology News(10 mins):